Brickell Biotech, Inc. (BBI): Price and Financial Metrics


Brickell Biotech, Inc. (BBI): $0.16

0.00 (2.05%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BBI to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

BBI POWR Grades


  • BBI scores best on the Sentiment dimension, with a Sentiment rank ahead of 63.87% of US stocks.
  • The strongest trend for BBI is in Value, which has been heading up over the past 28 days.
  • BBI's current lowest rank is in the Quality metric (where it is better than 9.13% of US stocks).

BBI Stock Summary

  • For BBI, its debt to operating expenses ratio is greater than that reported by merely 0.5% of US equities we're observing.
  • With a year-over-year growth in debt of -100%, Brickell Biotech Inc's debt growth rate surpasses only 0% of about US stocks.
  • Revenue growth over the past 12 months for Brickell Biotech Inc comes in at -77.83%, a number that bests only 1.49% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Brickell Biotech Inc, a group of peers worth examining would be ATNM, INFI, DRRX, ZSAN, and SONN.
  • Visit BBI's SEC page to see the company's official filings. To visit the company's web site, go to www.brickellbio.com.

BBI Valuation Summary

  • BBI's price/earnings ratio is -2; this is 105.48% lower than that of the median Healthcare stock.
  • Over the past 243 months, BBI's EV/EBIT ratio has gone up 17.3.
  • BBI's price/sales ratio has moved up 161 over the prior 243 months.

Below are key valuation metrics over time for BBI.

Stock Date P/S P/B P/E EV/EBIT
BBI 2021-08-31 188.4 2.8 -2.0 -1.2
BBI 2021-08-30 175.1 2.6 -1.9 -1.1
BBI 2021-08-27 178.3 2.7 -1.9 -1.1
BBI 2021-08-26 181.0 2.7 -1.9 -1.2
BBI 2021-08-25 181.0 2.7 -1.9 -1.2
BBI 2021-08-24 169.4 2.6 -1.8 -1.0

BBI Growth Metrics

    Its 2 year net cashflow from operations growth rate is now at -228.73%.
  • Its 5 year net cashflow from operations growth rate is now at -546.72%.
  • Its 4 year cash and equivalents growth rate is now at -22.3%.
Over the past 34 months, BBI's revenue has gone down $502,000.

The table below shows BBI's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 0.404 -36.148 -39.474
2021-09-30 0.327 -36.101 -40.772
2021-06-30 0.337 -28.949 -31.845
2021-03-31 0.793 -19.315 -25.815
2020-12-31 1.822 -20.034 -20.913
2020-09-30 2.464 -29.324 -24.41

BBI's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • BBI has a Quality Grade of D, ranking ahead of 9.13% of graded US stocks.
  • BBI's asset turnover comes in at 0.011 -- ranking 386th of 681 Pharmaceutical Products stocks.
  • AMPH, VTVT, and IONS are the stocks whose asset turnover ratios are most correlated with BBI.

The table below shows BBI's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.011 1 12.593
2021-03-31 0.025 1 11.420
2020-12-31 0.073 1 15.834
2020-09-30 0.116 1 40.527
2020-06-30 0.156 1 -6.335
2020-03-31 0.110 1 -1.800

BBI Price Target

For more insight on analysts targets of BBI, see our BBI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $5.50 Average Broker Recommendation 1.25 (Strong Buy)

BBI Stock Price Chart Interactive Chart >

Price chart for BBI

BBI Price/Volume Stats

Current price $0.16 52-week high $1.04
Prev. close $0.16 52-week low $0.14
Day low $0.16 Volume 2,275,900
Day high $0.16 Avg. volume 7,525,555
50-day MA $0.24 Dividend yield N/A
200-day MA $0.37 Market Cap 19.04M

Brickell Biotech, Inc. (BBI) Company Bio


Brickell Biotech, Inc., a clinical-stage pharmaceutical company, focuses on identifying, developing, and commercializing various prescription therapeutics for the treatment of debilitating skin diseases in the United States. The company's lead product candidate is sofpironium bromide that is in phase 3 clinical trial to treat patients with primary axillary hyperhidrosis. Its pipeline consists of potential novel therapeutics for hyperhidrosis and other prevalent dermatological conditions. Brickell Biotech, Inc. has a collaboration agreement with AnGes, Inc. for the development of a novel DNA vaccine candidate for COVID-19. The company was founded in 2009 and is headquartered in Boulder, Colorado.


BBI Latest News Stream


Event/Time News Detail
Loading, please wait...

BBI Latest Social Stream


Loading social stream, please wait...

View Full BBI Social Stream

Latest BBI News From Around the Web

Below are the latest news stories about Brickell Biotech Inc that investors may wish to consider to help them evaluate BBI as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Rise and shine, trader!

William White on InvestorPlace | March 2, 2022

Brickell Biotech, Carna Biosciences Ink Licensing Pact For STING inhibitors

Brickell Biotech Inc (NASDAQ: BBI ) has entered into an exclusive agreement with Carna Biosciences Inc to develop and commercialize Carna''s portfolio of oral Stimulator Interferon Genes (STING) antagonists. STING is a well-known mediator of innate immune responses. Excessive signaling through STING is linked to several diseases, ranging from autoimmune disorders, such as systemic lupus erythematosus and rheumatoid Full story available on Benzinga.com

Benzinga | February 2, 2022

Brickell Biotech Acquires Exclusive Global Rights to Portfolio of Novel STING Inhibitors Targeting Autoimmune and Inflammatory Diseases from Carna Biosciences

Lead STING inhibitor candidate, BBI-10, demonstrated dose-dependent cytokine reduction in nonclinical in vitro and in vivo studies providing strong proof-of-mechanism Agreement enhances Brickell’s pipeline in immunology and inflammation and leverages its drug development capabilities to advance Carna’s next-generation STING inhibitors BOULDER, Colo. and KOBE, Japan, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutic

Yahoo | February 2, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Good morning, trader!

William White on InvestorPlace | January 20, 2022

H.C. Wainwright Thinks Brickell Biotech’s Stock is Going to Recover

Brickell Biotech (BBI – Research Report) received a Buy rating and a $2.00 price target from H.C. Wainwright analyst Ram Selvaraju today. The company's shares closed last Friday at $0.21, close to its 52-week low of $0.20. According to TipRanks.com, Selvaraju has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -24.8% and a 20.6% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Aquestive Therapeutics, Oncternal Therapeutics, and Inovio Pharmaceuticals. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Brickell Biotech with a $2.00 average price target.

Brian Anderson on TipRanks | January 18, 2022

Read More 'BBI' Stories Here

BBI Price Returns

1-mo -30.50%
3-mo -26.94%
6-mo -48.17%
1-year -80.37%
3-year -98.01%
5-year -99.03%
YTD -30.10%
2021 -70.67%
2020 -47.97%
2019 -81.84%
2018 -35.52%
2017 -20.43%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6677 seconds.